Today, RPB-supported researchers at Washington University School of Medicine in St. Louis published a study identifying a biomarker that could help to predict glaucoma damage before vision loss.
An optic nerve with glaucoma damage, signified by loss of color and a round rim of pink tissue within the nerve.
Photo credit: CARLA J. SIEGFRIED / Washington University School of Medicine in St. Louis
"There hasn't been a reliable way to predict which patients with glaucoma have a high risk of rapid vision loss," said principal investigator Rajendra S. Apte, MD, PhD, the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences.
"But we've identified a biomarker that seems to correlate with disease severity in patients, and what that marker is measuring is stress to the cells rather than cell death. Other glaucoma tests are measuring cell death, which is not reversible, but if we can identify when cells are under stress, then there's the potential to save those cells to preserve vision," said Dr. Apte.
May 4, 2017
The new way to measure ocular aging opens treatment avenues for numerous eye diseases.
The American Academy of Ophthalmology (AAO) and Research to Prevent Blindness (RPB) today announced the 2023 recipients of the RPB/AAO Award for IRIS Registry Research.
RPB acknowledges the passing of a dedicated former Board member.
Patricia Ann D’Amore, PhD, MBA, is recognized for ground-breaking contributions to the field of vision research.
Dr. Akrit Sodhi at Johns Hopkins Medicine has published a new study showing promise for an experimental treatment to prevent or slow vision loss in people with diabetes.
RPB launches awards in data science and Diabetic Eye Disease.
Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.
General Info | Grants | News & Resources |